BAYN.SW Bayer AG (SIX) intraday falls 14% on volume spike 09 Mar 2026: watch CHF32.75 support

The BAYN.SW stock fell 14.49% intraday to CHF32.75 on 09 Mar 2026 after a sharp volume spike. Volume of 101 shares versus an average of 14 produced a relative volume of 128.07x, signalling outsized selling pressure on the SIX Switzerland tape. Traders should note the gap below the 50-day average CHF40.30, which connects this intraday move to recent earnings and guidance. We use volume-spike context to separate short-term liquidity events from structural valuation changes.

BAYN.SW stock intraday price and volume spike

Bayer AG (BAYN.SW) dropped to CHF32.75 on unusually high activity today, with reported volume 101 vs average 14. The one-day decline of -14.49% and relative volume 128.07x confirm a true intraday volume spike, not a thin-market fluke. This spike coincides with a move below short-term moving averages and compressed liquidity on the SIX exchange.

BAYN.SW stock catalysts and news

The move follows the company’s recent earnings announcement and subsequent market reaction on 04 Mar 2026, where EPS was -0.18 and PE printed -192.86, reflecting weak near-term profitability. Reuters coverage highlighted the stock reaction and provided real-time quotes for traders source. Institutional rebalancing and options flows likely amplified today’s volume spike.

BAYN.SW stock fundamentals and valuation

On fundamentals Bayer shows book value per share CHF26.53, market cap CHF34.10B, and price-to-sales 0.75, indicating valuation compression versus peers. Trailing metrics include free cash flow yield 8.59% and debt-to-equity 1.44, pointing to notable leverage. These ratios show a mixed picture: cash generation remains positive while return on equity is negative at -12.23%.

BAYN.SW stock technical view and support levels

Technical indicators show RSI 27.88 (oversold) and ADX 62.87 (strong trend), which supports continuation risk after the volume spike. Immediate support sits at CHF32.75 with resistance near the 50-day average CHF40.30. A sustained close below CHF32.75 raises the next target to CHF25.00; a recovery above CHF40.30 invalidates the bearish short-term setup.

BAYN.SW stock: Meyka grade and model forecast

Meyka AI rates BAYN.SW with a score out of 100: 66.35 (B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of CHF40.31 and a yearly target of CHF49.99. Compared with the current price CHF32.75, the one-year implied upside is 52.67%. Forecasts are model-based projections and not guarantees.

BAYN.SW stock risks, opportunities and a short-term trading idea

Key risks include continued margin pressure, negative EPS, and high net debt to EBITDA 4.76 which can amplify downside on weak demand. Opportunities are positive free cash flow yield and a diversified portfolio across Pharmaceuticals, Consumer Health and Crop Science. For volume-spike traders: watch for a reversion to mean near CHF40.30 or a follow-through breakdown below CHF32.75 before initiating new positions.

Final Thoughts

The intraday volume spike and the -14.49% drop to CHF32.75 make BAYN.SW stock a clear short-term event for traders. Fundamentals show mixed signals: free cash flow yield 8.59% and price-to-sales 0.75 provide value context while EPS -0.18 and debt metrics signal execution risk. Meyka AI’s forecast model projects CHF49.99 in 12 months, implying 52.67% upside versus today’s price, but this is model-based and not a guarantee. For intraday and short-term strategies, use the CHF32.75 support and CHF40.30 resistance as decision points and size positions to manage volatility. For investors, the Meyka grade 66.35 (B, HOLD) frames Bayer as a hold pending clearer earnings recovery and balance-sheet improvement. Follow live order flow on SIX and confirm any trend with volume above average before acting. Reuters coverage and the Meyka BAYN.SW stock page provide ongoing updates for traders and analysts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.